|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0069515,
umls-concept:C0087111,
umls-concept:C0205269,
umls-concept:C0242957,
umls-concept:C0278488,
umls-concept:C0282460,
umls-concept:C2347610
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1998-8-31
|
|
pubmed:abstractText |
To determine the toxicity, pharmacokinetics, response rate, and response duration of intravenous (i.v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BaloJJ,
pubmed-author:BaselgaJ MJM,
pubmed-author:BaughmanS ASA,
pubmed-author:GlaspyJ AJA,
pubmed-author:HazenG GGG,
pubmed-author:LiptonAA,
pubmed-author:PegramM DMD,
pubmed-author:SlamonD JDJ,
pubmed-author:TripathyDD,
pubmed-author:TwaddellTT,
pubmed-author:WeberB LBL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2659-71
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9704716-Adult,
pubmed-meshheading:9704716-Aged,
pubmed-meshheading:9704716-Antibodies, Monoclonal,
pubmed-meshheading:9704716-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:9704716-Antineoplastic Agents,
pubmed-meshheading:9704716-Breast Neoplasms,
pubmed-meshheading:9704716-Cisplatin,
pubmed-meshheading:9704716-Disease Progression,
pubmed-meshheading:9704716-Drug Resistance, Neoplasm,
pubmed-meshheading:9704716-Female,
pubmed-meshheading:9704716-Genes, erbB-2,
pubmed-meshheading:9704716-Humans,
pubmed-meshheading:9704716-Middle Aged
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
|
|
pubmed:affiliation |
Department of Medical Oncology, The University of California at Los Angeles, USA. mpegram@ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
